RIDD is a multi-centre blinded randomised study investigating repurposing anti-TNF in treating early Dupuytren's disease.
Dupuytren’s disease is a very common condition, affecting 4% of the general UK population. Following the initial appearance of nodules, the disease progresses, causing the fingers to contract towards the palm, which results in significant impairment of hand function. Currently there is no approved treatment for early disease.
We are trialling an intranodular injection of anti-TNF to control the progression of early Dupuytren’s disease. The team from the University of Oxford is led by Professor Nanchahal at the Kennedy Institute of Rheumatology. The RIDD trial is funded by the Health Innovation Challenge Fund (HICF). This is a parallel funding partnership between the Wellcome Trust and the Department of Health.
If you have any queries about the study please contact the team on email@example.com